NDT Advance Access originally published online on November 11, 2006
Nephrology Dialysis Transplantation 2007 22(1):47-52; doi:10.1093/ndt/gfl656
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
What's new in hypertension?
Munich General Hospitals, Ludwig Maximilians University Munchen and German Institute for High Blood Pressure Research, Heidelberg, Germany
Correspondence and offprint requests to: Johannes F. E. Mann, MD, Department of Nephrology and Hypertension, Munich General Hospitals, LMU, Kolner Platz 1, D – 80804 Munchen, Germany. Email: johannes.mann@kms.mhn.de
Keywords: blood pressure; cardiovascular; death; mortality; renal insufficiency; review; stroke
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
This editorial comment intends to inform readers of Nephrology Dialysis and Transplantation once a year on new information in the field of hypertension that has not been published in nephrological journals. We will review manuscripts from early 2005 to autumn 2006. Obviously, the choice of topics and manuscripts will be very subjective. Information on hypertension is published—apart from nephrology journals—in almost 10 specialty journals of hypertension and in many other areas; Medline lists 9973 citations in 2005 under the term ‘hypertension’, of which 1861 are reviews.
|
Human studies |
|---|
Are ß-blockers outdated as antihypertensive monotherapy?
Hypertension guidelines of national and international societies for decades recommended ß-adrenoceptor antagonists (ß-blockers) as first-line antihypertensive medication. This recommendation may change; in fact, in the very recently revised British hypertension guidelines, ß-blockers are not a first choice in the drug therapy of essential hypertension. Which study triggered this revolution? After all, there is no new data apart from Lindholm et al. [1
ß-blockers reduce blood pressure but increase stiffness of resistance arteries
Reduction in proteinuria, a surrogate marker for the treatment of essential hypertension?
Does tubular proteinuria in hypertensive people predict cardiovascular risk?
Do people with hypertension have to stop drinking coffee?
Should we start drug treatment in people with high-normal blood pressure?
Haemodynamic guidance of antihypertensive therapy improves blood pressure control
News on antihypertensive drug adherence
When to screen for sleep-disordered breathing in hypertension?
Reversible renal damage in people with primary hyperaldosteronism
|
Experimental studies |
|---|
Extracellular matrix as a cause—and not merely a consequence—of hypertension?
Inhibition of the renin–angiotensin system to prevent arterial aneurysms?
Intra- and extrarenal angiotensin type-1 receptors contribute equally to blood pressure regulation
A renin receptor contributes to hypertension in a transgenic rat
Angiotensin converting enzyme (ACE) homologue ACE2 may contribute to blood pressure regulation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. CHIRAS, E. D. PAPADAKIS, A. KATOPODI, E. CHATZIANESTI, K. FOURTOUNAS, S. PAPAKONSTANTINOU, I. THEODOROPOULOS, A. DAKOURAS, N. ZEREFOS, D. VALIS, et al. Platelet GP IIIA Polymorphism HPA-1 (PLA1/2) Is Associated with Hypertension as the Primary Cause for End-stage Renal Disease in Hemodialysis Patients from Greece In Vivo, January 1, 2009; 23(1): 177 - 181. [Abstract] [Full Text] [PDF]
|
|